Table 3.
Adjusted associations of AF status with risk of clinical outcomes stratified by sex, age, CHA2DS2-VASc score, and medication use.
| Subgroup | ESRD | Stroke or Systemic Thromboembolism | AMI | All-Cause Mortality | Cardiovascular Mortality | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Prevalent AF vs. Non-AF | Incident AF vs. Non-AF | Prevalent AF vs. Non-AF | Incident AF vs. Non-AF | Prevalent AF vs. Non-AF | Incident AF vs. Non-AF | Prevalent AF vs. Non-AF | Incident AF vs. Non-AF | Prevalent AF vs. Non-AF | Incident AF vs. Non-AF | |
| Age | ||||||||||
| Age < 65 | 1.48 (1.36–1.62) |
3.02 (2.75–3.31) |
1.93 (1.75–2.13) |
1.67 (1.52–1.83) |
1.68 (1.49–1.89) |
2.18 (1.97–2.42) |
1.98 (1.71–2.29) |
2.07 (1.83–2.33) |
3.27 (2.47–4.33) |
6.92 (5.01–9.56) |
| Age ≥ 65 | 1.30 (1.20–1.41) |
2.86 (2.63–3.11) |
1.88 (1.72–2.05) |
1.7 (1.53–1.89) |
1.11 (0.95–1.30) |
1.47 (1.23–1.77) |
1.78 (1.68–1.88) |
2.25 (2.12–2.40) |
2.92 (2.55–3.35) |
5.20 (4.51–5.98) |
| p for interaction | 0.029 | <0.001 | 0.104 | 0.650 | 0.037 | <0.001 | <0.001 | 0.529 | 0.436 | 0.610 |
| Gender | ||||||||||
| Female | 1.48 (1.36–1.61) |
3.27 (2.99–3.57) |
1.66 (1.45–1.89) |
2.15 (1.89–2.44) |
0.98 (0.76–1.26) |
2.20 (1.75–2.77) |
1.56 (1.44–1.70) |
2.72 (2.51–2.96) |
3.64 (3.05–4.35) |
8.28 (6.95–9.87) |
| Male | 1.27 (1.18–1.38) |
2.92 (2.68–3.17) |
2.08 (1.90–2.26) |
1.34 (1.20–1.49) |
1.43 (1.22–1.66) |
1.89 (1.61–2.21) |
1.69 (1.58–1.80) |
1.93 (1.8–2.07) |
2.70 (2.28–3.20) |
2.96 (2.47–3.55) |
| p for interaction | 0.005 | 0.119 | <0.001 | <0.001 | 0.013 | 0.012 | 0.430 | <0.001 | 0.004 | <0.001 |
| CHA2DS2-VASc Score | ||||||||||
| CHA2DS2-VASc Score ≤3 | 1.65 (1.54–1.77) |
3.37 (3.13–3.62) |
2.40 (2.18–2.64) |
2.31 (2.09–2.55) |
1.92 (1.62–2.28) |
3.52 (2.98–4.14) |
1.96 (1.83–2.10) |
2.13 (1.99–2.28) |
3.17 (2.67–3.77) |
5.78 (4.87–6.85) |
| CHA2DS2-VASc Score >3 | 1.02 (0.92–1.13) |
3.23 (2.9–3.59) |
1.54 1.38–1.72) |
2.04 (1.79–2.34) |
1.04 (0.60–1.78) |
2.34 (1.89–2.89) |
1.44 (1.33–1.56) |
3.10 (2.87–3.35) |
1.56 (1.28–1.89) |
8.41 (7.12–9.93) |
| p for interaction | <0.001 | 0.408 | <0.001 | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Renin-angiotensin system inhibitors use | ||||||||||
| Non-user | 1.47 (1.34–1.6) |
2.46 (2.23–2.71) |
1.99 (1.87–2.11) |
2.03 (1.9–2.18) |
1.58 (1.47–1.69) |
2.68 (2.5–2.88) |
1.68 (1.57–1.81) |
2.57 (2.39–2.77) |
4.79 (3.99–5.76) |
4.97 (4.08–6.06) |
| User | 1.44 (1.33–1.56) |
3.52 (3.24–3.81) |
1.29 (1.16–1.43) |
2.09 (1.88–2.33) |
1.18 (0.74–1.87) |
1.03 (0.54–1.98) |
1.76 (1.63–1.89) |
2.02 (1.87–2.18) |
2.07 (1.75–2.46) |
5.27 (4.51–6.16) |
| p for interaction | 0.909 | <0.001 | <0.001 | <0.001 | 0.7437 | <0.001 | 0.4018 | 0.3070 | <0.001 | 0.847 |
Atrial fibrillation (AF); angiotensin-converting enzyme inhibitor (ACEI); angiotensin II receptor blocker (ARB); end-stage renal disease (ESRD); acute myocardial infarction (AMI).